Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12143979 | 0.89 | RXFP1 (0.52) | RXFP1KDM4EPOLBALDH1A1HPGD | |
| Bromide SCHEMBL1366991 | 0.88 | RXFP1 (0.51) | RXFP1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL23534402 | 0.86 | RXFP1 (0.50) | RXFP1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL26664194 | 0.86 | RXFP1 (0.50) | RXFP1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL23534351 | 0.86 | RXFP1 (0.50) | RXFP1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL3698300 | 0.86 | RXFP1 (0.71) | RXFP1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL23534256 | 0.85 | RXFP1 (0.49) | RXFP1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL22438227 | 0.85 | RXFP1 (0.49) | RXFP1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL23535382 | 0.84 | RXFP1 (0.48) | RXFP1KDM4EPOLBALDH1A1HPGD | |
| SCHEMBL16705088 | 0.83 | KDM4E (0.51) | RXFP1KDM4EPOLBALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111448190-B | Substituted indole compounds | 百时美施贵宝公司 | 2023-09-26 | — | — | CN | disclosed |
| US-11739098-B2 | Substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739098-B2 | Substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739098-B2 | Substituted indole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-29 | — | — | US | disclosed |
| EP-3710440-B1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230098244-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3710440-A1 | SUBSTITUTED INDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111448190-A | Substituted indole compounds | 百时美施贵宝公司 | 2020-07-24 | — | — | CN | disclosed |
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | RXFP1 90/4885KDM4E 2059/4885POLB 4658/4885 |
| US-20230098244-A1 | SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, HTR7 | RXFP1 337/4885KDM4E 2026/4885POLB 3971/4885 |
| US-20210253593-A1 | SUBSTITUTED INDOLE COMPOUNDS | TLR7, TLR1, HTR7 | RXFP1 337/4885KDM4E 2026/4885POLB 3971/4885 |
| US-11739098-B2 | Substituted indole compounds | TLR7, TLR1, HTR7 | RXFP1 337/4885KDM4E 2026/4885POLB 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.